Recent decisions from various UPC divisions provide valuable guidance for parties seeking to amend their cases or patents. The decisions emphasize that it is crucial for parties to know how to distinguish between the rules...more
The UPC decides that the defendant’s financial situation and location matter.
On 30 October 2023, the Munich Central Division of the UPC (the Court) issued an order stating that NanoString must provide security to Harvard...more
12/20/2023
/ Enforcement Actions ,
EU ,
Ex Parte ,
Intellectual Property Protection ,
Life Sciences ,
Litigation Fees & Costs ,
Patent Litigation ,
Patents ,
Revocation ,
UK ,
Unified Patent Court
On 18 October 2023, the Düsseldorf local division of the UPC in myStromer vs. Revolt Zycling (UPC_CFI_177/2023) imposed a EUR26,500 penalty on Revolt for breaching a preliminary injunction. This is the first penalty payment...more
In Astellas v. Osaka University (UPC_CFI_75/2023), by decision of 21 September 2023, the UPC Munich Central Division denied a third party access to the case file, specifically to Astellas’ revocation action, which was...more
10/19/2023
/ European Patent Office ,
Germany ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Patent Litigation ,
Patent Ownership ,
Patents ,
Revocation ,
Trade Secrets ,
Unified Patent Court
The decision concerns the time of filing and admissibility of a revocation action at the Central Division when a parallel infringement action is filed at a local division (Art. 33(4) UPCA). Art 33(4) UPCA states that...more
8/25/2023
/ Amgen ,
Amgen v Sanofi ,
Appeals ,
Dismissals ,
EU ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Luxembourg ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Revocation ,
Sanofi-Aventis
When, finally, the UPC goes live on 1 June 2023, it will be a game changer for European patent litigation. The UPC will improve efficiencies for organisations who usually litigate in multiple European jurisdictions. With one...more
In this episode of our Exclusively Life Sciences webinar series, our experts from our EU team will share best practices for innovators to protect their competitive advantage when generics enter the market....more